Burkitt lymphoma (BL) 
Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) constitute the majority of nonlymphoblastic B-cell lymphomas in the pediatric population. BL is separated into 3 clinical variants in the most recent World Health Organization (WHO) classification: endemic BL, sporadic BL, and immunodeficiency-associated BL. 1 The majority of pediatric BL cases in the United States are of the sporadic type. By contrast, DLBCL is a fairly homogeneous entity, and, although it is seen primarily in adults, it constitutes about 20% of childhood non-Hodgkin lymphoma (NHL) cases. 2 The distinction between BL and DLBCL in children is of more than just academic interest. The clinical behavior can differ between these 2 groups, and the treatment regimens are different in a subset of clinical trials. 3, 4 BL and DLBCL usually can be distinguished easily at the morphologic level. 1 Cases of BL typically are composed of medium-sized, monotonous tumor cells with nuclei that are round and roughly the size of a histiocyte nucleus. The tumor cells have clumped chromatin and multiple nucleoli, and they infiltrate as a diffuse sheet. BL characteristically has a high mitotic index and a "starry-sky" pattern as a consequence of numerous interspersed benign phagocytic histiocytes. DLBCL also infiltrates in a diffuse manner; however, the tumor cells are large and more pleomorphic than those seen in cases of BL. The mitotic index is variable in cases of DLBCL and a starry-sky pattern is not prominent in most cases.
However, there is a subset of cases with a spectrum of morphologic features that are intermediate between BL and DLBCL. These cases have been classified variably: undifferentiated lymphoma, non-Burkitt (Rappaport); small noncleaved cell, non-Burkitt (Working Formulation); and high-grade B-cell lymphoma, Burkitt-like (Revised European-American classification of lymphoid neoplasms). 5, 6 The current WHO classification considers them as a variant of BL (atypical Burkitt/Burkitt-like). 1 It is this latter group that can cause diagnostic difficulty, especially in small biopsy specimens showing artifactual distortion, and these cases often require additional studies for an accurate diagnosis.
Various ancillary studies have been used to characterize and distinguish BL and DLBCL. These include immunohistochemical, cytogenetic, and molecular techniques. [7] [8] [9] [10] [11] [12] These studies have suggested that there are immunophenotypic differences that might aid in the distinction of these entities 7, [10] [11] [12] ; however, the majority of the reports have involved adult patient groups, with few studies focusing primarily on pediatric patients. As such, we studied the immunohistochemical expression of 6 proteins (c-myc, CD10, bcl-6, bcl-2, CD138, and MIB-1) in a series of 33 cases of morphologically classic pediatric BL and 20 cases of morphologically classic pediatric DLBCL to determine characteristic immunophenotypic profiles for each type of lymphoma.
Materials and Methods

Case Selection and Morphologic Assessment
Prospective cases from a large clinical trial focusing on mature B-cell NHL (CCG [Children's Cancer Group] 5961-FAB [French-American-British] 96 Treatment of Mature BCell Lymphoma/Leukemia), for which formalin-fixed, paraffin-embedded archival tissue was available, were reviewed independently by 4 hematopathologists (M.F., J.N., M.A.L., S.L.P.), and 53 cases were selected that displayed classic morphologic features in accordance with the criteria specified in the WHO classification and Revised EuropeanAmerican classification of lymphoid neoplasms 1, 6 and in which diagnostic consensus was reached by all 4 pathologists. All cases were blinded and any patient identifiers removed. The selected samples included 33 cases of BL and 20 cases of DLBCL. These represented children from the ages of 4 to 17 years, and as required by the study, none of the patients had primary or acquired immunodeficiencies.
Diagnostically difficult cases that were not morphologically distinguishable as BL or DLBCL were specifically not included in the first phase of this study.
Immunohistochemical Methods
In all 53 cases, 4-µm-thick, formalin-fixed, paraffinembedded tissue sections were prepared for antibody application by heat-induced epitope retrieval using citrate buffer (pH 6.0) for 3 minutes in an electric pressure cooker. Monoclonal antibodies against c-myc, bcl-6, CD10, bcl-2, CD138, and MIB-1 ❚Table 1❚ were subsequently applied and developed using a diaminobenzidine detection kit. In addition, an amplification process (Ventana Enhance kit, Ventana, Tucson, AZ) was used for a subset of the antibodies before diaminobenzidine detection (c-myc, CD10, bcl-6, and bcl-2).
All slides were stained on an autostainer (Ventana). Slides then were counterstained with hematoxylin, dehydrated, and coverslipped with a permanent mounting medium. Staining in each case was scored quantitatively as follows: 0, no staining of tumor cells; 1+, more than 0% to 25% or fewer; 2+, more than 25% to 50% or fewer; 3+, more than 50% to 75% or fewer; and 4+, more than 75%. Staining for bcl-2 was also assigned an intensity score (0-4+), and cases were classified as positive for bcl-2 if the score for the percentage of tumor cells staining or the intensity score was 2+ or greater. To evaluate staining, at least 10 high-power fields including tumor were evaluated and combined to reach an overall percentage of tumor cell staining. In all cases, fields throughout the tumor sections were evaluated. When multiple sections of tumor were available, stains were performed on 2 separate sections and evaluated independently before combination of data to give a final score. In 19 of 33 cases of BL and 16 of 20 cases of DLBCL, 2 sections from the same tumor biopsy specimen were evaluated for staining. In addition, the MIB-1 stain was assigned a percentage value that was calculated by scoring 500 tumor cell nuclei for the presence or complete absence of signal and converting to a percentage. Non-tumor cell nuclei were not included in the MIB-1 analysis.
Statistical analysis of the data was performed by using a Pearson χ 2 analysis to compare the predictive values of each marker analyzed individually and within a panel. 
Analysis of Morphologically Indeterminate Cases
To test the usefulness of immunohistochemical staining patterns observed in the index cases, 4 cases of pediatric CD20+ NHL that could not be classified further owing to extensive biopsy artifact (all small biopsy specimens with extensive crush and cautery artifact) were analyzed using a proposed staining panel of c-myc, bcl-2, and MIB-1 to determine whether the staining patterns would favor a diagnosis of DLBCL or BL. The stains were evaluated as described, with the exception of the MIB-1 stain that, owing to crushing and technical distortion of the biopsy specimens, did not permit the counting of 500 individual cells. The MIB-1 stain was interpreted low (0%-50%), medium (51%-90%), or high (>90%) in the tumor cells for these biopsy specimens.
Results
Patient Population
The study was performed on diagnostic biopsy materials for 53 patients enrolled in the CCG 5961-FAB 96 Treatment of Mature B-Cell Lymphoma/Leukemia study, including 33 cases of BL and 20 cases of DLBCL. The patients with BL included 19 boys and 14 girls with an age range of 6 to 14 years. The patients with DLBCL included 14 boys and 7 girls ranging in age from 8 to 17 years. Clinical staging placed all cases into clinical group B (tumor not totally resected, no central nervous system or bone marrow involvement). Of 33 cases of BL, 22 were extranodal disease (predominantly involving the gastrointestinal tract), and 3 of 20 cases of DLBCL were extranodal (2 tonsils and 1 case in the large intestine).
Pathology and Immunohistochemical Staining
Evaluation of H&E-stained sections in each case showed classic morphologic features of BL and DLBCL, respectively ❚Image 1❚. All 4 hematopathologists reviewing these cases were required to independently agree on the diagnosis for a case to be included in the study. None of the cases included in the study had ambiguous morphologic features that would raise the possibility of atypical BL/Burkitt-like lymphoma or mature B-cell NHL, not otherwise specified. For 53 cases, paraffin-embedded material was available for immunohistochemical staining (33 BL cases and 20 DLBCL cases). The immunohistochemical staining results are tabulated in ❚Table 2❚ and ❚Table 3❚ and are displayed in graphic form in ❚Figure 1❚.
In all positively stained cases, c-myc displayed nuclear localization. Expression of c-myc differed significantly between BL and DLBCL with 30 (91%) of 33 cases of BL showing staining in the majority of cells (≥50%), while only 2 (10%) of 20 DLBCL cases showed a similar degree of staining (P < .0001; Image 1, Figure 1A ). Absent or minimal staining for c-myc (≤25% of tumor cells stained) was seen in only 3 cases of BL (9%), but this low level of staining was noted in the majority of DLBCL cases (11/20 [55%] ). However, substantial overlap in the expression of c-myc was noted between BL and DLBCL (Figure 1 ), severely limiting its use as a single discriminatory marker.
Staining for CD10 showed cytoplasmic membrane localization. There was no significant difference in the expression of CD10 between the BL and DLBCL cases, with all 33 cases of BL showing expression in more than 50% of the cells (30/33 displayed ≥75% staining), whereas 20 of 20 cases of DLBCL showed more than 75% CD10 staining. This extensive degree of overlap indicated that CD10 was not a useful individual marker to distinguish between BL and DLBCL.
Staining for bcl-2 displayed a characteristic cytoplasmic localization, and positive staining was defined as an intensity of 2+ or more or 25% or more of tumor cells stained. While bcl-2 was positive in 6 (32%) of 19 DLBCL cases, only 1 (4%) of 25 cases of morphologically classic BL displayed strong bcl-2 staining (P < .02) ( Figure 1B The mean percentage of tumor cell nuclei staining with the MIB-1 antibody differed significantly between BL (99%; SD, 3%; range, 90%-100%) and DLBCL (56%; SD, 24%; range, 20%-95%) cases (Image 1, Figure 1C ). Specifically, 23 (82%) of 28 BL cases had proliferation indices (PIs) of 99% or greater, while the remaining 5 cases fell in the 90%-99% range. By contrast, only 2 (10%) of 20 DLBCL cases had PIs of more than 90% (both 95%), and none reached 99% (P < .0001). Again, the use of MIB-1 staining demonstrated a very significant trend for higher MIB-1 staining percentages in the BL cases, but a degree of overlap with 10% of the DLBCL cases studied indicated that it was not useful as a single discriminatory stain for making a diagnosis of BL vs DLBCL.
Based on the substantial overlap in staining observed in each of the individual markers studied, panels of the markers demonstrating the most significant differences in staining were tested for the ability to positively predict a diagnosis of BL or DLBCL (Table 3) . By using this approach, it would seem that the use of a panel containing MIB-1, bcl-2, and possibly c-myc will provide a very high positive predictive value for a diagnosis of BL. Lack of expression of one of these markers in the panel provided a significant negative predictive value for a diagnosis of BL.
Staining of Morphologically Indeterminate Cases
To test the usefulness of the proposed immunohistochemical panels, 4 cases of pediatric NHL that were strongly CD20+ but could not be classified further owing to marked architectural distortion (small biopsy specimens with extensive cautery and crush artifact) were analyzed by using a panel of immunohistochemical stains including c-myc, bcl-2, and MIB-1 and analyzed for informative patterns of reactivity that could support a diagnosis of BL or DLBCL. Staining was interpreted as described in the "Analysis of Morphologically Indeterminate Cases" section. The results ❚Table 4❚ suggest that all tumors analyzed represented BL, exhibiting a c-myc-positive, bcl-2-negative, and high MIB-1-staining phenotype, rather than DLBCL. This interpretation was supported by the detection of a c-myc translocation identified as t(8;14)(q23;q21) in cytogenetic studies performed at the time of diagnosis in 3 of the 4 cases studied. The other case (case 2) did not have cytogenetics performed at the time of biopsy, and the results of fluorescent in situ hybridization using a c-myc probe performed on the biopsy material were considered not interpretable owing to the quality of specimen preservation.
Discussion
BL and DLBCL constitute the majority of nonlymphoblastic B-cell lymphomas in children and adolescents. The distinction between BL and DLBCL might be important in determining an optimal treatment strategy. In children and adolescents, these 2 forms of mature B-cell NHL have a different prognosis and in some cooperative group clinical trials might have different treatment protocols. Children and adolescents with BL have been treated with shorter, more intense chemotherapy regimens that have resulted in significant improvement in disease-free survival rates (≥80%). [13] [14] [15] [16] However, children with disseminated large cell lymphoma in at least 1 trial showed an inferior 3-year survival of only 65%. 17 From an investigative standpoint, most pediatric cooperative group studies of high-grade lymphomas have stratified patients based primarily on a morphologic diagnosis without requiring ancillary studies, such as immunohistochemical analysis or genetic studies, to support the morphologic impression. This has resulted in a variable degree of diagnostic heterogeneity in these studies. More accurate classification of BL cases, with particular emphasis on molecular abnormalities and immunophenotype, might result in a better understanding of tumor behavior and response to therapy by providing a more uniform tumor diagnostic grouping. 3 Furthermore, better identification and classification of tumors might allow development of tumor-specific therapeutic regimens. Classic cases of BL and DLBCL have fairly distinct morphologic appearances. However, in a subset of cases, the distinction cannot be made with certainty by morphologic assessment alone, and ancillary studies are required. These studies include cytogenetic analyses and polymerase chain reaction assays. In the case of BL, these are used primarily to assess for the presence of a c-myc translocation, whose detection lends very strong support for a diagnosis of BL. However, these assays are not always available, they increase the turnaround time, and are costly. By contrast, immunohistochemical stains are relatively inexpensive and can be performed in a matter of hours on paraffin-embedded tissue samples in most pathology laboratories. Reports in adult patients indicate that there might be distinctive antigenic expression profiles in BL and DLBCL 7, 8, 18 ; however, there are few comparative immunohistochemical studies in pediatric patients with these tumors. 9 As such, we conducted this comparative study to determine whether pediatric patients with BL and DLBCL have distinctive antigenic expression profiles that could aid in the specific diagnosis of these entities. Analysis of the immunohistochemical expression of 6 proteins (c-myc, CD10, bcl-6, bcl-2, CD138, and MIB-1) in classic cases of pediatric BL (33 cases) and DLBCL (20 cases) showed specific protein expression profiles for BL and DLBCL that could be useful in morphologically indeterminate cases. BL and DLBCL displayed significant differences in the immunohistochemical expression of c-myc, bcl-2, and MIB-1 ( Table 2 ). It should be noted that statistical significance for an individual marker predicting diagnosis was seen only with 4+ staining with c-myc, absent staining with bcl-2, and MIB-1 expression of 100%. The combined patterns of expression of these antigens seemed to be much more useful for distinguishing between DLBCL and BL, using a panel that includes c-myc, bcl-2, and MIB-1. Expression of c-myc and 100% MIB-1 with absent bcl-2 was highly predictive of a BL diagnosis. In contrast, a similar proportion of BL and DLBCL cases stained for bcl-6 and CD10, and no cases of either tumor showed expression of CD138, suggesting that these antibodies are not useful for discriminating between these tumors.
Expression of c-myc protein is increased characteristically in BL as a consequence of c-myc translocation from 8q24 to the immunoglobulin heavy chain locus on chromosome 14 or, in a minority of cases, to the light chain loci on chromosomes 2 and 22. This finding also can be observed in up to 15% of large cell lymphomas. 10 In our study, 91% of the BL cases (30/33) showed strong immunohistochemical expression of c-myc in more than 50% of the tumor cells, while only 25% (5/20) of the DLBCL cases showed a similar level of c-myc expression. Of note, 3 of 5 DLBCL cases with this degree of c-myc expression also had PIs of 80% or greater. Our results contrast with the findings of Hutchison et al, 9 who demonstrated c-myc in 9 (69%) of 13 pediatric BL cases and in all 12 pediatric DLBCL cases. The differences may be due in part to the 2 different c-myc antibodies used. The c-myc antibody in their study was obtained from a different company (Novocastra), and, thus, it might recognize different antigenic epitopes with different specificities. In addition, Hutchison et al 9 defined positive staining as being more than 20% of cells staining, whereas we used a more stringent definition of 50% or more of the cells staining. This definition of positive staining also might have contributed to a higher percentage of c-myc-positive DLBCL cases in the study by Hutchison et al. 9 If we had included cases in our study that displayed 25% or more staining, our DLBCL c-myc-positive cases would total 9 (45%) of 20.
CD10 is a membrane-associated neutral endopeptidase. 11 In a study of CD10 expression in paraffin-embedded tissue samples, Dogan and coworkers 7 noted positive staining for CD10 in all 20 BL cases studied. Of their 54 DLBCL cases, 21 (39%) expressed CD10; however, the expression was much more frequent in cases that had a known history of follicular lymphoma, with 9 of 10 such cases staining for CD10. 7 Similarly, we found CD10 expression in all 33 of our BL cases and all 20 DLBCL cases. The significance of CD10 staining our DLBCL cases is uncertain because none of the patients with DLBCL had a known history of follicular lymphoma, and, in general, follicular lymphoma is distinctly uncommon in the pediatric age range. However, this finding might suggest a follicular center cell origin for most or all of these pediatric DLBCL cases.
The oncoprotein bcl-2 has been shown to be useful in distinguishing between reactive and neoplastic B-cell proliferations. 12, 18 While the majority of small B-cell neoplasms express bcl-2, most cases of BL do not. Lai et al 18 studied bcl-2 expression in 778 paraffin-embedded lymphoma samples; they found bcl-2 expression in 75 (70.1%) of 107 DLBCL cases and in none (0%) of 5 BL cases. Similarly, Hutchison et al 9 found bcl-2 expression in 50% of pediatric DLBCL cases and in none of their 13 pediatric BL cases. Our findings show a similar very low to absent rate of bcl-2 expression in BL (1/25 [4%] of our cases). While the proportion of bcl-2-positive cases was significantly higher in DLBCL (7/19 [37%] ) than in BL (1/25 [4%]), this was lower than the proportion of bcl-2-positive DLBCL seen in the aforementioned studies. 12, 18 The MIB-1 monoclonal antibody recognizes the proliferation-associated antigen Ki-67, and staining for MIB-1 is used to determine the PI of a tumor cell population. Cases of BL typically display a very high growth fraction with PIs on the order of 99% to 100%. 1, 19 Most DLBCL cases have PIs greater than 40%; however, only a small subset have a PI approaching that of BL. In adults with high-stage large cell NHL, a PI of 80% or more has been associated with a poorer prognosis. 20 In our study, BL cases had a mean PI of 99% (SD, 3%; range, 90%-100%), while the PI of DLBCL was significantly lower, 56% (SD, 24%; range, 20%-95%). The BL cases were very tightly clustered, with the majority displaying PIs of 100% (23/28 cases), while the DLBCL cases showed a large PI range (20%-95%). Only 4 cases of DLBCL had PIs of 80% or more (80%, 85%, 95%, and 95%), and 3 of the 4 DLBCL cases with PIs of 80% or more had 4+ staining for c-myc, suggesting an association between these proteins in pediatric DLBCL. Given the association between high PIs and poor prognosis in DLBCL, 20 it is interesting to note that adult cases of DLBCL with high clinical stage and high or high-intermediate risk also have been shown to have a statistically significant correlation with c-myc expression. 21 The protein bcl-6 has been shown to be expressed by lymphoid cells of follicle center derivation. 22 In a recent report of adult cases, bcl-6 gene product expression was shown to identify 2 populations of DLBCL, with cases overexpressing bcl-6 having a significantly longer median overall survival. 23 Dogan et al 7 studied the immunohistochemical expression of bcl-6 protein in 17 cases of BL and found positive staining in all cases. In addition, 39 (83%) of 47 DLBCL cases stained for bcl-6 in their study, and similar to the pattern seen in their CD10+ cases, bcl-6 staining was seen in all 9 cases of DLBCL with a history of follicular lymphoma. 7 We found a rate of bcl-6 staining in DLBCL (15/20 [75%] ) similar to that seen in their study, and this was virtually identical to that seen in our BL cases (23 [7/19] ). Thus, a panel of immunostains including these markers (c-myc, bcl-2 and MIB-1) might prove beneficial in classifying morphologically challenging cases that have features indeterminate between BL and DLBCL.
Absent or minimal c-myc expression (≤25% cells positive) was common in DLBCL (55% [11/20] ) cases, but rare in BL (3% and 6% of cases, respectively) and, thus, would strongly favor the diagnosis of DLBCL vs BL. Since a significant proportion of cases of DLBCL expressed c-myc (25% [5/20] ), the presence of this marker alone would not preclude a diagnosis of DLBCL. The presence of bcl-2 would strongly favor DLBCL, although the absence of bcl-2 staining does not provide valuable information, because more than 60% of DLBCL cases were negative for this marker in our study.
Finally, a PI of 99% or greater strongly supports a diagnosis of BL vs DLBCL; on the other hand, a small overlap of cases occurs with PIs in the 90%-95% range, with 5 (18%) of 28 BL cases and 2 (10%) of 20 DLBCL cases in our study falling in this range. However, the presence of extensive c-myc expression in 3 of 4 DLBCL cases with PIs of 80% or more suggests that even in morphologically classic cases of pediatric DLBCL, there may be a subset of cases that have molecular features more typical of BL. Further studies, including molecular analyses, might permit better classification of these morphologically ambiguous cases.
These results suggest that use of an immunohistochemical panel including stains for c-myc, bcl-2, and MIB-1 will provide ancillary support for a specific diagnosis of BL or DLBCL in children and adolescents. The use of this approach in morphologically indeterminate cases, usually owing to small samples or poor tissue handling, might permit a more definitive diagnosis to be given and permit more accurate prognostic information to be provided to patients. A small initial study testing this hypothesis was performed on 4 cases that could not be diagnosed definitely as BL or DLBCL based on extensive crush artifact and small biopsy specimens. Based on clinical manifestations and molecular fluorescent in situ hybridization studies that demonstrated a c-myc translocation in 3 of the 4 cases, it would be predicted that these lymphomas most likely represented BL. The immunophenotypic profile further supported the impression of BL and would have added greater diagnostic certainty. Although all the cases studied were treated as mature B-cell neoplasms without the need to differentiate between a diagnosis of BL or DLBCL, it is hoped that the ability to better define the subtypes of NHL in children and adolescents will lead to more specific therapeutic approaches in future treatment protocols.
